Pay in 4 interest-free payments of $6.34 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Substantial evidence supports the short-term efficacy of glucose-lowering treatments
1 In the REIMAGINE 2 trial, the most commonly reported AEs were GI-related, occurring in 405/603 (67.2%) participants in the CagriSema 2.4 mg/2.4 mg group, 326/605 (53.9%) participants in the semaglutide 2.4 mg group, 60/152 (39.5%) participants in the cagrilintide 2.4 mg group, 329/594 (55.4%) participants in the CagriSema 1 mg/1 mg group, 288/608 (47.4%) participants in the semaglutide 1 mg group, and 42/149 (28.2%) participants in the placebo group
While some people maintain most of their weight loss, others may regain a significant portion of the weight they lost
However, there are no well-controlled studies in pregnant women, so this medication is generally recommended during pregnancy only when clearly needed
